title: Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?
authors.affiliation: Haemato-oncology Division, 2nd Department of Pediatrics, Semmelweis University, Tuzolto 7-9., 1094, Budapest, Hungary. kovi@gyer2.sote.hu
authors.forename: Gábor T
authors.initials: GT
authors.lastname: Kovács
authors.forename: Hajna
authors.initials: H
authors.lastname: Erlaky
authors.forename: Kornélia
authors.initials: K
authors.lastname: Tóth
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Horváth
authors.forename: Judit
authors.initials: J
authors.lastname: Szabolcs
authors.forename: Monika
authors.initials: M
authors.lastname: Csóka
authors.forename: László
authors.initials: L
authors.lastname: Jókúti
authors.forename: Dániel
authors.initials: D
authors.lastname: Erdélyi
authors.forename: Judit
authors.initials: J
authors.lastname: Müller
mesh_terms: D000208:Acute Disease; D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced* / Q000517:prevention & control; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002648:Child; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008297:Male; D011929:Razoxane / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D018943:Anthracyclines; D002317:Cardiovascular Agents; D011929:Razoxane